AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 221 min read$VCYT

Leite John sold $161K of VCYT

Leite John (Global Chief Commercial Off) sold 4,015 shares of VERACYTE, INC. (VCYT) at $40.00 ($0.16M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Leite John
Published Sep 22, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VCYT
Neutral
high confidence
Mentioned
$VCYT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCYTNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting low immediate impact.

02

Market read

Insider sale is routine; unlikely to move the stock significantly.

03

What to watch

Potential future insider transactions or broader ownership changes not captured here.

Relevance 3/10Novelty 3/10Timing: post‑market filing on Sep 22, 2026

Background

Form 4 filings disclose insider trades; investors monitor them for signals.

Company-level read

Ticker impact

$VCYTNeutralHigh confidence
Context

Officer John Leite sold 4,015 shares for $160,600 via a 10b5-1 plan on Sep 21, 2026.

Expected impact

No material move; potential slight downward pressure.

Evidence & confidence

Sale size is small relative to float and disclosed under a pre‑arranged plan, indicating no urgent insider concern.

Market effects

Sector

Minimal effect on the genomics diagnostics sector.

Regional

No regional impact.

Global

Limited relevance to global markets.

Counterpoint

What could challenge this read

If the insider is offloading shares ahead of undisclosed concerns, a short‑term dip could be larger.

Key entities

  • Company
    Veracyte, Inc.

    NASDAQ‑listed genomics diagnostics firm.

  • Insider
    John Leite

    Global Chief Commercial Officer at Veracyte.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VCYT insider trading history →

Related articles

JUL 30
$VCYTHigh

VERACYTE, INC. (VCYT): Results of Operations and Financial Condition

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS

SEC EDGAR 8-K6 min